Online inquiry

IVTScrip™ mRNA-Anti-TNF, ABP 501(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1167MR)

This product GTTS-WQ1167MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, ABP 501(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ1167MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ355MR IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 20A11-9mer-ALB11
GTTS-WQ1497MR IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ACD79B-VCMMAE
GTTS-WQ5631MR IVTScrip™ mRNA-Anti-TNF, CDP870(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CDP870
GTTS-WQ13178MR IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PF-04518600
GTTS-WQ12100MR IVTScrip™ mRNA-Anti-CD38, MOR-03087(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MOR-03087
GTTS-WQ10445MR IVTScrip™ mRNA-Anti-MSTN, LY-2495655(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY-2495655
GTTS-WQ218MR IVTScrip™ mRNA-Anti-IL13, 13C5.5(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 13C5.5
GTTS-WQ14554MR IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SAR156597
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW